Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes

Journal of Clinical Investigation

Volumn 108, Issue 7, 2001, Pages 1001-1013

  Yamauchi, Toshimasa ^a   Waki, Hironori ^a   Kamon, Junji ^a   Murakami, Koji ^b   Motojima, Kiyoto ^c   Komeda, Kajuro ^d   Miki, Hiroshi ^a   Kubota, Naoto ^a   Terauchi, Yasuo ^a   Tsuchida, Atsuko ^d   Tsuboyama Kasaoka, Nobuyo ^e   Yamauchi, Naoko ^a   Ide, Tomohiro ^b   Hori, Wataru ^b   Kato, Shigeaki ^f   Fukayama, Masashi ^a   Akanuma, Yasuo ^g   Ezaki, Osamu ^e   Itai, Akiko ^h   Nagai, Ryozo ^a   Kimura, Satoshi ^a   Tobe, Kazuyuki ^a   Kagechika, Hiroyuki ^f   Shudo, Koichi ^f   Kadowaki, Takashi ^a   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g INSTITUTE FOR ADULT DISEASES   (Japan)

^h Inst of Medicinal Molecular Design   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR BLOCKING AGENT; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; 2,2-BIS(4-GLYCIDYLOXYPHENYL)PROPANE; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; BENZOIC ACID DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR; BIPHENYL DERIVATIVE; CELL RECEPTOR; DIAZEPINYLBENZOIC ACID; EPOXIDE; FATTY ACID; NICOTINIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; ROSIGLITAZONE; TETRALIN DERIVATIVE; THIAZOLE DERIVATIVE;

ADIPOSE TISSUE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; FAT INTAKE; FATTY ACID METABOLISM; HYPERGLYCEMIA; INSULIN RESISTANCE; LIVER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SKELETAL MUSCLE; WEIGHT GAIN; ANIMAL; CELL STRAIN 3T3; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; MOUSE MUTANT;

3T3 CELLS; ADIPOSE TISSUE; ANIMALS; BENZOIC ACIDS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; EPOXY COMPOUNDS; FATTY ACIDS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LEPTIN; MICE; MICE, KNOCKOUT; NICOTINIC ACIDS; OBESITY; RECEPTORS, ADRENERGIC, BETA-3; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 85047685428     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI12864     Document Type: Article

References (55)

1. Roles of PPARs in health and disease
2. PPARgamma: An essential regulator of adipogenesis and modulator of fat cell function
3. Adipogenesis and obesity: Rounding out the big picture
4. Recent update on the PPAR alpha-null mouse
5. PPARgamma, the ultimate thrifty gene
6. An antidiabetic thiazotidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ
7. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
8. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
9. Rosiglitazone Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
11. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
12. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency
13. A Pro 12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
14. The Pro 12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes
15. The common PPARgamma Pro 12Ala polymorphism is associated with decreased risk of type 2 diabetes
16. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation
17. Retinoid X receptor-antagonistic diazepinylbenzoic acids
18. Upregulation of liver uncoupling protein-2 mRNA by either fish oil feeding or fibrate administration in mice
19. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner
20. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents
21. Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice
22. A novel insulin sensitizer acts as a coligand for peroxisome proliferacor-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats
23. Convergence of transforming growth factorbeta and vitamin D signaling pathways on SMAD transcriptional coactivators
24. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
25. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
26. Improved and simplified tissue extraction method for quantitating long-chain acyl-coenzme A thioesters with picomolar detection using high-performance liquid chromatography
27. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
28. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
29. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor
30. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha
31. Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression
32. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
33. A genetic dissection of the retinoid signalling pathway in the mouse
34. Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation: Usefulness of leptin for the treatment of obesity-associated diabetes
35. Obesity in the new millennium
36. Functional antagonism between CCAAT/enhancer binding protein-alpha and peroxisome proliferator-activated receptor-gamma on the leptin promoter
37. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
38. Leptin-specific patterns of gene expression in white adipose tissue
39. Thiazolidinediones inhibit the expression of beta3-adrenergic receptors at a transcriptional level
40. The role of TNFalpha and TNF receptors in obesity and insulin resistance
41. The hormone resistin links obesity to diabetes
42. Regulation of fatty acid homeostasis in cells: Novel role ofleptin
43. Cellular mechanisms of insulin resistance
44. Life without white fat: A transgenic mouse
45. Generalized lipodystrophy, congenital and acquired (lipoatrophy)
46. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
47. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity
48. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting
49. Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor α mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes
50. Unraveling the mechanism of action of thiazolidinediones
51. The mechanisms by which both heterozygous PPARγ deficiency and PPARγ agonist improve insulin resistance
52. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake
53. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
54. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway